MA35043B1 - Formulation pharmaceutique comprenant de l'inositol - Google Patents

Formulation pharmaceutique comprenant de l'inositol

Info

Publication number
MA35043B1
MA35043B1 MA36334A MA36334A MA35043B1 MA 35043 B1 MA35043 B1 MA 35043B1 MA 36334 A MA36334 A MA 36334A MA 36334 A MA36334 A MA 36334A MA 35043 B1 MA35043 B1 MA 35043B1
Authority
MA
Morocco
Prior art keywords
inositol
pharmaceutical formulation
isomer
dispersions
suspensions
Prior art date
Application number
MA36334A
Other languages
English (en)
Inventor
Vittorio Unfer
Original Assignee
Lo Li Pharma Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lo Li Pharma Srl filed Critical Lo Li Pharma Srl
Publication of MA35043B1 publication Critical patent/MA35043B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant des solutions, suspensions ou dispersions d'inositol ou d'un isomère de celui-ci dans un véhicule comprenant de la gélatine, du glycérol, ou leurs mélanges.
MA36334A 2011-03-22 2012-03-21 Formulation pharmaceutique comprenant de l'inositol MA35043B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000445A ITMI20110445A1 (it) 2011-03-22 2011-03-22 Formulazione farmaceutica comprendente inositolo.
PCT/EP2012/054960 WO2012126931A1 (fr) 2011-03-22 2012-03-21 Formulation pharmaceutique comprenant de l'inositol

Publications (1)

Publication Number Publication Date
MA35043B1 true MA35043B1 (fr) 2014-04-03

Family

ID=43977111

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36334A MA35043B1 (fr) 2011-03-22 2012-03-21 Formulation pharmaceutique comprenant de l'inositol

Country Status (22)

Country Link
US (1) US20140010870A1 (fr)
EP (2) EP3178474B1 (fr)
CL (1) CL2013002700A1 (fr)
CY (2) CY1122980T1 (fr)
DK (2) DK2502622T3 (fr)
EA (1) EA026746B1 (fr)
ES (2) ES2798267T3 (fr)
HR (2) HRP20200792T1 (fr)
HU (2) HUE051001T2 (fr)
IL (1) IL228465B (fr)
IT (1) ITMI20110445A1 (fr)
LT (2) LT3178474T (fr)
MA (1) MA35043B1 (fr)
ME (1) ME03750B (fr)
MX (1) MX2013010812A (fr)
PE (1) PE20141011A1 (fr)
PL (2) PL3178474T3 (fr)
PT (2) PT3178474T (fr)
RS (2) RS60650B1 (fr)
TN (1) TN2013000373A1 (fr)
UA (1) UA115425C2 (fr)
WO (1) WO2012126931A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20163025A1 (it) 2016-04-29 2017-10-29 Sochim Int S P A Composizione per il trattamento della sindrome dell’ovaio policistico
CN109982691A (zh) * 2016-10-06 2019-07-05 韩国迪外天然健康株式会社 包含松醇、d-手性肌醇或它们的类似化合物作为有效成分的用于改善、预防或治疗女性更年期症状的组合物
US11898184B2 (en) * 2017-09-07 2024-02-13 Sweet Sense Inc. Low glycemic sugar composition
US11484540B2 (en) 2017-11-23 2022-11-01 Biosearch. S.A. Method for increasing embryo implantation rate in a female subject suffering polycystic ovary syndrome
CA3108838A1 (fr) * 2018-08-22 2020-02-27 Societe Des Produits Nestle S.A. Composition comprenant des isomeres d'inositol et son utilisation
US20220296534A1 (en) * 2019-08-30 2022-09-22 Societe Des Produits Nestle S.A. Scyllo-inositol and b-cell mediated disorders
EP4034092A1 (fr) * 2019-09-24 2022-08-03 Société des Produits Nestlé S.A. Scyllo-inositol et son utilisation en tant que sensibilisateur à l'insuline
RU2757220C1 (ru) * 2020-06-03 2021-10-12 Общество с ограниченной ответственностью "ОКТАВА ХОЛДИНГ" Фармацевтическая композиция для профилактики и лечения синдрома поликистозных яичников
RU2771426C1 (ru) * 2021-05-03 2022-05-04 Румиса Рамзановна Бериханова Способ коррекции дислипидемии у женщин с метаболическим синдромом в периоде менопаузального перехода

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8305693D0 (en) * 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
EP0465508B1 (fr) * 1989-03-08 2000-05-31 The University Of Virginia Patent Foundation Preparation pharmaceutique pour diabetiques resistant a l'insuline
TW282398B (fr) * 1993-12-22 1996-08-01 Bristol Myers Squibb Co
AU4802800A (en) * 1999-04-27 2000-11-10 Insmed Pharmaceuticals, Inc. Compositions and methods for improving insulin sensitivity and glucose metabolism in mammals
DE60115005T2 (de) * 2000-04-19 2006-07-27 Genentech Inc., San Francisco Formulierungen mit verzögerter freisetzung enthaltend wachstumshormon
KR101156789B1 (ko) * 2004-07-30 2012-06-18 와쿠나가 세이야쿠 가부시키 가이샤 젤라틴 피막용 조성물, 젤라틴 피막, 및 이를 이용한 캡슐제
EP1902710A4 (fr) * 2005-07-04 2009-12-02 Univ Tokyo Medical & Dental Composition pharmaceutique et composition de boisson comprenant de la l-arginine
US20070104801A1 (en) * 2005-11-07 2007-05-10 Ivf Online Llc Fertility and anti-aging supplement for the fertility health of females and males
AU2006311685A1 (en) * 2005-11-07 2007-05-18 Jaffe, Russell M Compositions for regulating metabolic disorders and methods of use thereof
ITRM20070341A1 (it) * 2007-06-20 2008-12-21 Lo Li Pharma Srl Formulazione integrativa inofolic finalizzata al controllo dell'induzione dell'ovulazione in programmi di procreazione medicalmente assistita
US20120232003A1 (en) * 2009-03-13 2012-09-13 Takahashi Joseph S Compositions and methods for diabetes treatment
PT2542224E (pt) * 2010-03-01 2014-10-03 Ratiopharm Gmbh Composição farmacêutica oral que contém etexilato de dabigatrana

Also Published As

Publication number Publication date
IL228465B (en) 2018-01-31
EP3178474B1 (fr) 2020-03-18
EP3178474A1 (fr) 2017-06-14
CY1122980T1 (el) 2021-10-29
ES2798267T3 (es) 2020-12-10
ES2806937T3 (es) 2021-02-19
EP2502622B1 (fr) 2020-06-10
HRP20200792T1 (hr) 2020-07-24
CY1123134T1 (el) 2021-10-29
MX2013010812A (es) 2014-03-21
EA201301061A1 (ru) 2014-02-28
PT3178474T (pt) 2020-05-06
HUE049942T2 (hu) 2020-11-30
TN2013000373A1 (en) 2015-01-20
PT2502622T (pt) 2020-06-29
DK2502622T3 (da) 2020-09-07
RS60650B1 (sr) 2020-09-30
LT3178474T (lt) 2020-05-11
PL2502622T3 (pl) 2020-11-16
PL3178474T3 (pl) 2020-09-21
HUE051001T2 (hu) 2021-01-28
WO2012126931A1 (fr) 2012-09-27
IL228465A0 (en) 2013-12-31
PE20141011A1 (es) 2014-08-27
US20140010870A1 (en) 2014-01-09
DK3178474T3 (da) 2020-06-08
ITMI20110445A1 (it) 2012-09-23
EP2502622A1 (fr) 2012-09-26
UA115425C2 (uk) 2017-11-10
RS60377B1 (sr) 2020-07-31
HRP20201048T1 (hr) 2020-10-16
CL2013002700A1 (es) 2014-07-11
EA026746B1 (ru) 2017-05-31
ME03750B (fr) 2021-04-20
LT2502622T (lt) 2020-07-27

Similar Documents

Publication Publication Date Title
MA35043B1 (fr) Formulation pharmaceutique comprenant de l'inositol
MA37740A1 (fr) Seringue
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA37538B1 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MA38248A1 (fr) Compositions pesticides et procédés associés
MA43187B1 (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MA45450B1 (fr) Formulations d'anticorps anti-cd19
MA47664A1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
MA37840B1 (fr) Immunoconjugués comprenant des anticorps anti-cd79b
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
MY166045A (en) Abeta antibody formulation
MA38960A1 (fr) Formulations d'anticorps anti-pdl1
MA38554A3 (fr) Anticorps bispécifiques dirigés contre fap et dr5, anticorps spécifiques dirigés contre dr5 et leurs procédés d'utilisation
MA37975B2 (fr) Inhibiteurs de synthase de glucosylcéramide
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
MA35898B1 (fr) Anticorps anti-lrp5 et leurs procédés d'utilisation
MA38273A1 (fr) Thérapie de combinaison avec des anticorps anti-her3
MA44550B1 (fr) Anticorps anti-acide téichoique de la paroi cellulaire et conjugués associés
EP4293116A3 (fr) Fibrinogène liquide stable
CL2012002948A1 (es) Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado.
WO2014153459A3 (fr) Hap fluorescente : colorant de diagnostic pour noyaux vhb dans des cellules
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA34840B1 (fr) Dérivés monoterpènes de chalcone ou de dihydrochalcone, et leur utilisation en tant qu'agents de dépigmentation
ES2543850A2 (es) Uso de complejos metálicos miméticos de SOD como agentes alimentarios y como cosméticos